New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Enanta Pharmaceuticals, Inc. (ENTA) vs Rocket Pharmaceuticals, Inc. (RCKT)

Enanta Pharmaceuticals, Inc. and Rocket Pharmaceuticals, Inc. are both Biotechnology companies. Enanta Pharmaceuticals, Inc. and Rocket Pharmaceuticals, Inc. are of similar size ($235.6M and $232.7M). Across the 10 metrics below, Rocket Pharmaceuticals, Inc. leads on 6 and Enanta Pharmaceuticals, Inc. on 4.

Valuation

Metric ENTA RCKT Biotechnology median
P/E n/m n/m 8.49
P/S 3.52 — 8.56
P/B 2.19 0.69 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 0.43 — 8.00
Earnings yield (30.94%) (7.27%) (35.81%)
Free cash flow yield (19.29%) (71.12%) (25.41%)

Profitability

Metric ENTA RCKT Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (99.01%) — 0.00%
Net margin (108.33%) — 0.00%
Free cash flow margin (67.88%) — 0.00%
Return on equity (94.19%) (5.04%) (51.58%)
Return on assets (24.54%) (4.10%) (45.91%)
Return on invested capital 0.00% (111.24%) 0.00%

Growth

Metric ENTA RCKT Biotechnology median
Revenue growth (TTM) (3.56%) — 7.20%
EPS growth (last fiscal year) 38.72% 26.37% 29.04%
Revenue growth, 5-year CAGR (8.28%) — 9.54%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ENTA RCKT Biotechnology median
Debt to equity 0.00 0.15 0.00
Current ratio 3.78 7.26 4.79
Net debt to EBITDA 3.37 0.77 1.01

Dividend

Metric ENTA RCKT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ENTA RCKT Biotechnology median
Market cap 232.69m 235.60m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack